Department of Thoracic Surgery, Zhong Shan Hospital, Shanghai Medical School, Fudan University, Shanghai, People's Republic of China.
Clin Lung Cancer. 2012 Jul;13(4):280-7. doi: 10.1016/j.cllc.2011.11.005. Epub 2011 Dec 16.
By using immunohistochemistry in tissue microarrays of 137 cases, we evaluated the prognostic power of a 3-marker epithelial-mesenchymal transition–related model in patients with stage I non-small-cell lung cancer who underwent radical surgical resection. The Twist/Slug/Foxc2 coexpression model accurately prognosticated these patients and may be helpful in refining current treatment strategy for stage I non-small-cell lung cancer.
Lung cancer is the leading cause of cancer-related death in the world. Only about 60% of patients with stage I non-small-cell lung cancer (NSCLC) can be cured by surgery alone. Current clinical and molecular markers are inadequate prognosticators. We developed a 3-marker model that closely approximates survival probability of patients with stage I NSCLC.
Expression of Twist, Slug, and Foxc2 was assessed by immunohistochemistry in tissue microarrays that contained paired tumor and peritumoral lung tissue from 137 patients who underwent surgical resection for stage I NSCLC. The prognostic value of Twist, Slug, and Foxc2, and the cumulative effects of the 3 markers on survival were evaluated.
Increased expression of Twist, Slug, and Foxc2 was observed in 38.0%, 18.2%, and 27.7% of primary tumors, respectively. Overexpression of Twist, Slug, and Foxc2 in stage I NSCLC was associated with a worse overall survival (P = .001, P = .002, P < .001, respectively) and correlated with a shorter recurrence-free survival (P < .001, P = .001, P < .001 respectively). The cumulative influence of these markers on outcome was analyzed; a combination of more than 2 positive markers was an independent predictor of recurrence-free and overall survival (P = .002 and P = .009, respectively).
The Twist/Slug/Foxc2 model is useful in predicting survival of stage I NSCLC and may be helpful in refining current treatment strategy.
通过对 137 例病例组织微阵列中的免疫组织化学检测，我们评估了 3 个上皮-间质转化相关标志物在接受根治性手术切除的 I 期非小细胞肺癌患者中的预后能力。Twist/Slug/Foxc2 共表达模型能准确预测这些患者的预后，可能有助于完善 I 期非小细胞肺癌的当前治疗策略。
肺癌是全球癌症相关死亡的主要原因。只有约 60%的 I 期非小细胞肺癌（NSCLC）患者可以通过单独手术治愈。目前的临床和分子标志物不是很理想的预后预测指标。我们开发了一个 3 个标志物模型，该模型能非常接近地预测 I 期 NSCLC 患者的生存概率。
对 137 例接受 I 期 NSCLC 手术切除的患者的组织微阵列中的 Twist、Slug 和 Foxc2 的表达进行了免疫组织化学检测，这些微阵列包含配对的肿瘤和肿瘤周围肺组织。评估了 Twist、Slug 和 Foxc2 的预后价值以及这 3 个标志物对生存的累积影响。
在原发性肿瘤中分别观察到 Twist、Slug 和 Foxc2 的表达增加，其比例分别为 38.0%、18.2%和 27.7%。I 期 NSCLC 中 Twist、Slug 和 Foxc2 的过表达与总生存时间较差相关（P=0.001、P=0.002、P<0.001，分别），与无复发生存时间较短相关（P<0.001、P=0.001、P<0.001，分别）。分析了这些标志物对结果的累积影响；两个以上阳性标志物的组合是无复发生存和总生存的独立预测因子（P=0.002 和 P=0.009，分别）。
Twist/Slug/Foxc2 模型可用于预测 I 期 NSCLC 的生存情况，可能有助于完善当前的治疗策略。
